by Gian Luigi Lenzi
The first paper that I would like to point out to Neuropenews readers concerns a neurological syndrome that often I have personally disregarded, or linked to similar “foggy” presentations such as the Chronic Fatigue Syndrome. Serra J, Collado A, Solà R et al, have published in ANNALS OF NEUROLOGY, 12 february 2014, Vol 75, Issue 2, pages 196-208, a paper “Hyperexcitable C nociceptors in fibromyalgia” that initially escaped my attention (it was published one year ago) and that indicates how in fibromyalgia there is more than many neurologists (at least myself) previously thought.
The second paper has been published in the New England Journal of Medicine, 2015, 372, pages 528-536, by Saver JL, Starkman S, Eckstein M et al, for the FAST-MAG trials, with the title “Prehospital Use of Magnesium Sulfate as Neuroprotection in acute Stroke”. The clinical results are negative, but the approach, that is to give neuroprotection ASAP to acute stroke patients, appears in the right direction, provided that … there is NO occlusion in the symptomatic artery, as in all the cases of the EXTEND-IA Study, reported by Campbell, Mitchell, Kleining et al, in the same journal, New England Journal of Medicine, February 11, 2015. In fact, if an arterial occlusion (of the internal carotid or middle cerebral artery) is present, how may the neuroprotector drug be able to reach the endangered tissue?
